QGC006 - Best-in-class - optimized treatment of hypertension as monotherapy

QGC006, “best-in-class” future product

The company plans to strengthen its pipeline by developing a second generation products to manage the life cycle of BAPAI technology products. The objective of this program is to identify within this new class a back-up product of the firibastat that could become a “Best in Class” product.

Quantum Genomics has selected a second drug candidate, QGC006, which is ten times more potent than firibastat in inhibiting the activity of Aminopeptidase A.